Literature DB >> 18446262

The Janus-face kynurenic acid.

Eva Rózsa1, Hermina Robotka, László Vécsei, József Toldi.   

Abstract

Kynurenic acid is an endogenous product of the tryptophan metabolism. Studies on the mechanism of its action have revealed that kynurenic acid at high concentrations is a competitive antagonist of the N-methyl-D-aspartate receptor and acts as a neuroprotectant in different neurological disorders. This in vitro investigation was designed to show that kynurenic acid acts differently at low concentrations. In vitro electrophysiological examinations on the young rat hippocampus confirmed the well-known finding that kynurenic acid in micromolar concentrations exerts an inhibitory effect. However, in nanomolar concentrations, kynurenic acid does not give rise to inhibition, but in fact facilitates the field excitatory postsynaptic potentials. The results available so far are compatible with the idea that kynurenic acid in the concentration range between a few hundred nanomolar and micromolar displays different effects. Its probable action on different receptors, inducing the different mechanisms, is discussed. The findings strongly suggest the neuromodulatory role of kynurenic acid under both physiological and pathological circumstances.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446262     DOI: 10.1007/s00702-008-0052-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  37 in total

1.  Kynurenine metabolism in Alzheimer's disease.

Authors:  H Baran; K Jellinger; L Deecke
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

2.  Kynurenic acid has a dual action on AMPA receptor responses.

Authors:  Christina Prescott; Autumn M Weeks; Kevin J Staley; Kathryn M Partin
Journal:  Neurosci Lett       Date:  2006-04-27       Impact factor: 3.046

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

Review 5.  Kynurenic acid antagonists and kynurenine pathway inhibitors.

Authors:  T W Stone
Journal:  Expert Opin Investig Drugs       Date:  2001-04       Impact factor: 6.206

6.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

7.  Kynurenic acid and schizophrenia.

Authors:  Sophie Erhardt; Lilly Schwieler; Göran Engberg
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

8.  Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

Authors:  R Pellicciari; B Natalini; G Costantino; M R Mahmoud; L Mattoli; B M Sadeghpour; F Moroni; A Chiarugi; R Carpenedo
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

9.  Electrochemical and in vitro evaluation of the redox-properties of kynurenine species.

Authors:  Gregory I Giles; Catriona A Collins; Trevor W Stone; C Jacob
Journal:  Biochem Biophys Res Commun       Date:  2003-01-17       Impact factor: 3.575

10.  Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex.

Authors:  Csaba Kiss; Paul D Shepard; Ferenc Bari; Robert Schwarcz
Journal:  Brain Res       Date:  2004-03-26       Impact factor: 3.252

View more
  40 in total

1.  Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse.

Authors:  Valentina Vengeliene; Nazzareno Cannella; Tatiane Takahashi; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2016-07-30       Impact factor: 4.530

2.  Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72).

Authors:  M Lukács; K Warfvinge; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2017-03-23       Impact factor: 7.277

Review 3.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 4.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

Review 5.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

6.  Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils.

Authors:  Zoltán Tiszlavicz; Balázs Németh; Ferenc Fülöp; László Vécsei; Katalin Tápai; Imre Ocsovszky; Yvette Mándi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-19       Impact factor: 3.000

7.  A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study.

Authors:  Máté Marosi; Dávid Nagy; Tamás Farkas; Zsolt Kis; Eva Rózsa; Hermina Robotka; Ferenc Fülöp; László Vécsei; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2009-12-02       Impact factor: 3.575

Review 8.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

Review 9.  The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors.

Authors:  Zsófia Majláth; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2013-12-18       Impact factor: 3.575

10.  Kynurenic acid and its derivatives are able to modulate the adhesion and locomotion of brain endothelial cells.

Authors:  Eszter Lajkó; Bernadett Tuka; Ferenc Fülöp; István Krizbai; József Toldi; Kálmán Magyar; László Vécsei; László Kőhidai
Journal:  J Neural Transm (Vienna)       Date:  2018-01-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.